Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Buildings (2016)

Lisata Therapeutics' Buildings history spans 4 years, with the latest figure at $13.0 million for Q4 2016.

  • For Q4 2016, Buildings rose 12.98% year-over-year to $13.0 million; the TTM value through Dec 2016 reached $13.0 million, up 12.98%, while the annual FY2016 figure was $13.0 million, 12.98% up from the prior year.
  • Buildings reached $13.0 million in Q4 2016 per LSTA's latest filing, up from $11.5 million in the prior quarter.
  • In the past five years, Buildings ranged from a high of $13.0 million in Q4 2016 to a low of $9.9 million in Q4 2012.
  • Average Buildings over 3 years is $11.4 million, with a median of $11.5 million recorded in 2015.
  • Peak YoY movement for Buildings: rose 0.24% in 2012, then rose 12.98% in 2016.
  • A 3-year view of Buildings shows it stood at $9.9 million in 2012, then grew by 15.97% to $11.5 million in 2015, then grew by 12.98% to $13.0 million in 2016.
  • Per Business Quant, the three most recent readings for LSTA's Buildings are $13.0 million (Q4 2016), $11.5 million (Q4 2015), and $9.9 million (Q4 2012).